Mar 20 2024 Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.
The SemaCyte Multiplexing Platform uses optical barcodes to tag and differentiate individual cells and cell types while preserving natural morphology, with each microcarrier capable of carrying millions of unique identifiers. Each barcode can be viewed using brightfield microscopy and digitally deconvoluted using the company’s Semalyse software, which is included within the platform.
The Multiplexing Platform has been developed to further leverage Semarion’s innovative microcarrier technology, SemaCytes, in advancing drug discovery workflows. SemaCytes are a novel class of cell carriers created to address fundamental limitations in adherent cell assaying workflows using microchip fabrication technologies, nanomagnetism, and smart materials.
Following the success of the Early Adopter Program for the SemaCyte Microcarrier Platform in October 2023, researchers can now apply for early access to the Multiplexing Platform. As part of the program, Semarion will partner with early adopters to integrate the platform into existing workflows. To apply to be part of the Early Adopter Program, please visit the following link: https://www.semarion.
Education Education Latest News, Education Education Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: wallpapermag - 🏆 36. / 67 Read more »